A holistic approach to targeting disease with polymeric nanoparticles

Nature Reviews Drug Discovery

Volumn 14, Issue 4, 2015, Pages 239-247

  Cheng, Christopher J ^a,b   Tietjen, Gregory T ^a   Saucier Sawyer, Jennifer K ^a   Saltzman, W Mark ^a  

^a Yale University   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOSAN; CYANOACRYLATE; MACROGOL; NANOPARTICLE; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIDE; POLYMER; POLYSTYRENE;

BLOOD BRAIN BARRIER; CHEMICAL COMPOSITION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG ELIMINATION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; LIGAND BINDING; MOLECULARLY TARGETED THERAPY; NANOENGINEERING; NANOMEDICINE; OPSONIZATION; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; REVIEW; ANIMAL; CHEMISTRY; HUMAN; PROCEDURES;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; POLYMERS;

EID: 84926421904     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4503     Document Type: Review

References (134)

1. Liu X. M., et al. Syntheses of click PEG-dexamethasone conjugates for the treatment of rheumatoid arthritis. Biomacromolecules 11, 2621-2628 (2010
2. Wong C., et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl Acad. Sci. USA 108, 2426-2431 (2011
3. Kamaly N., Xiao Z., Valencia P. M., Radovic-Moreno A. F. & Farokhzad O. C. Targeted polymeric therapeutic nanoparticles: design development and clinical translation. Chem. Soc. Rev. 41, 2971-3010 (2012
4. Shi J., Xiao Z., Kamaly N. & Farokhzad O. C. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Accounts Chem. Res. 44, 1123-1134 (2011
5. Bertrand N., Wu J., Xu X., Kamaly N. & Farokhzad O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2-25 (2014
6. Lammers T., Kiessling F., Hennink W. E. & Storm G. Drug targeting to tumors: principles pitfalls and (pre-) clinical progress. J. Control. Release 161, 175-187 (2012
7. Iyer A. K., Khaled G., Fang J. & Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11, 812-818 (2006
8. Hrkach J., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl Med. 4, 128ra39 (2012
9. Davis M. E., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010
10. Merki E., et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 118, 743-753 (2008
11. Cheng C. J., et al. MicroRNA silencing for cancer therapy targeted to the tumor microenvironment. Nature http://dx.doi.org/10.1038/nature13905 (2014
12. Salvati A., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nature Nanotechnol. 8, 137-143 (2013
13. Kunjachan S., et al. Passive Versus Active Tumor Targeting Using RGD- And NGR-modified Polymeric Nanomedicines. Nano Lett. 14, 972-981 (2014
14. Cheng Z., Al Zaki A., Hui J. Z., Muzykantov V. R. & Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338, 903-910 (2012
15. Crielaard B. J., Lammers T., Schiffelers R. M. & Storm G. Drug targeting systems for inflammatory disease: one for all all for one. J. Control. Release 161, 225-234 (2012
16. Bertrand N. & Leroux J. C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J. Control. Release 161, 152-163 (2012
17. Bernal G. M., et al. Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine 10, 149-157 (2014
18. Desai P. R., et al. Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J. Control. Release 170, 51-63 (2013
19. Vij N., et al. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J. Nanobiotechnol. 8, 22 (2010
20. Weiser J. R. & Saltzman W. M. Controlled release for local delivery of drugs: barriers and models. J. Control. Release 190, 664-673 (2014
21. Fleming A. B. & Saltzman W. M. Pharmacokinetics of the carmustine implant. Clin. Pharmacokinet. 41, 403-419 (2002
22. Sawyer A. J., et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatmeny of intracranial tumors. Drug Deliv. Transl Res. 1, 34-42 (2011
23. Zhou J., et al. Highly penetrative drug-loaded nanocarriers improve treatment of glioblastoma. Proc. Natl Acad. Sci. USA 110, 11751-11756 (2013
24. Nance E. A., et al. A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci. Transl Med. 4, 149ra119 (2012
25. Neeves K. B., Sawyer A. J., Foley C. P., Saltzman W. M. & Olbricht W. L. Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles. Brain Res. 1180, 121-132 (2007
26. Sawyer A. J., Piepmeier J. M. & Saltzman W. M. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J. Biol. Med. 79, 141-152 (2006
27. Allard E., Passirani C. & Benoit J. P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30, 2302-2318 (2009
28. Lam M. F., Thomas M. G. & Lind C. R. Neurosurgical convection-enhanced delivery of treatments for Parkinson's disease. J. Clin. Neurosci. 18, 1163-1167 (2011
29. Stiles D. K., et al. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp. Neurol. 233, 463-471 (2012
30. Wang Y. C., et al. Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury. Biomaterials 29, 4546-4553 (2008
31. Li H., et al. A PEDF N terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp. Eye Res. 83, 824-833 (2006
32. Kaur I. P. & Kakkar S. Nanotherapy for posterior eye diseases. J. Control. Release 193, 100-112 (2014
33. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality?. J. Pharm. Sci. 99, 21-50 (2010
34. Hadam J., Aoun E., Clarke K. & Wasko M. C. Managing risks of TNF inhibitors: an update for the internist. Cleve. Clin. J. Med. 81, 115-127 (2014
35. Moghimi S. M. & Bonnemain B. Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography. Adv. Drug Deliv. Rev. 37, 295-312 (1999
36. Irvine D. J., Swartz M. A. & Szeto G. L. Engineering synthetic vaccines using cues from natural immunity. Nature Mater. 12, 978-990 (2013
37. Moghimi S. M. & Rajabi-Siahboomi A. R. Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues. Prog. Biophys. Mol. Biol. 65, 221-249 (1996
38. Hawley A. E., Illum L. & Davis S. S. Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block co polymers. FEBS Lett. 400, 319-323 (1997
39. Kreuter J., Nefzger M., Liehl E., Czok R. & Voges R. Distribution and elimination of poly(methyl methacrylate) nanoparticles after subcutaneous administration to rats. J. Pharm. Sci. 72, 1146-1149 (1983
40. Toita R., et al. Biodistribution of 125I labeled polymeric vaccine carriers after subcutaneous injection. Bioorg. Med. Chem. 21, 5310-5315 (2013
41. Moghimi S. M., et al. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett. 344, 25-30 (1994
42. DeMuth P. C., et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nature Mater. 12, 367-376 (2013
43. Reddy L. H., Sharma R. K. & Murthy R. S. Enhanced tumour uptake of doxorubicin loaded poly(butyl cyanoacrylate) nanoparticles in mice bearing Dalton's lymphoma tumour. J. Drug Target. 12, 443-451 (2004
44. Cartiera M. S., et al. Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol. Pharm. 7, 86-93 (2010
45. Gugulothu D., Kulkarni A., Patravale V. & Dandekar P. pH sensitive nanoparticles of curcumin- celecoxib combination: evaluating drug synergy in ulcerative colitis model. J. Pharm. Sci. 103, 687-696 (2014
46. Yoo M. K., et al. Targeted delivery of chitosan nanoparticles to Peyer's patch using M cell-homing peptide selected by phage display technique. Biomaterials 31, 7738-7747 (2010
47. Gundogdu E. & Yurdasiper A. Drug transport mechanism of oral antidiabetic nanomedicines. Int. J. Endocrinol. Metab. 12, e8984 (2014
48. Pridgen E. M., et al. Transepithelial transport of Fc targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci. Transl Med. 5, 213ra167 (2013
49. Mohammad A. K., Amayreh L. K., Mazzara J. M. & Reineke J. J. Rapid lymph accumulation of polystyrene nanoparticles following pulmonary administration. Pharm. Res. 30, 424-434 (2013
50. Woodrow K. A., et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nature Mater. 8, 526-533 (2009
51. Steinbach J. M., Weller C. E., Booth C. J. & Saltzman W. M. Polymer nanoparticles encapsulating siRNA for treatment of HSV 2 genital infection. J. Control. Release 162, 102-110 (2012
52. Lai S. K., Wang Y. Y. & Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61, 158-171 (2009
53. Ensign L. M., et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl Med. 4, 138ra79 (2012
54. Navath R. S., et al. Injectable PAMAM dendrimer-PEG hydrogels for the treatment of genital infections: formulation and in vitro and in vivo evaluation. Mol. Pharm. 8, 1209-1223 (2011
55. Yang M., et al. Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. 3, 1044-1052 Adv. Healthc. Mater. (2013
56. Blum J. S., et al. Topical treatment of K ras and Pten mediated intravaginal cancer with camptothecin-loaded nanoparticles. Drug Deliv. Transl Res. 1, 383-394 (2011
57. das Neves J., et al. Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice. Pharm. Res. 31, 1834-1845 (2014
58. Cu Y., Booth C. J. & Saltzman W. M. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J. Control. Release 156, 258-264 (2011
59. Lai S. K., et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl Acad. Sci. USA 104, 1482-1487 (2007
60. das Neves J., Amiji M. & Sarmento B. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3, 389-399 (2011
61. Cu Y. & Saltzman W. M. Drug delivery: stealth particles give mucus the slip. Nature Mater. 8, 11-13 (2009
62. Cu Y. & Saltzman W. M. Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol. Pharm. 6, 173-181 (2009
63. GuhaSarkar S. & Banerjee R. Intravesical drug delivery: challenges current status opportunities and novel strategies. J. Control. Release 148, 147-159 (2010
64. Barthelmes J., Perera G., Hombach J., Dunnhaupt S. & Bernkop-Schnurch A. Development of a mucoadhesive nanoparticulate drug delivery system for a targeted drug release in the bladder. Int. J. Pharm. 416, 339-345 (2011
65. Martin D. T., et al. Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer. Mol. Cancer Ther. 13, 71-81 (2014
66. Peppas N. A. & Huang Y. Nanoscale technology of mucoadhesive interactions. Adv. Drug Deliv. Rev. 56, 1675-1687 (2004
67. Wang Y. Y., et al. Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure. PLoS ONE 6, e21547 (2011
68. Kirpotin D. B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732-6740 (2006
69. Pirollo K. F. & Chang E. H. Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol. 26, 552-558 (2008
70. He C., Hu Y., Yin L., Tang C. & Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31, 3657-3666 (2010
71. Sahay G., Alakhova D. Y. & Kabanov A. V. Endocytosis of nanomedicines. J. Control. Release 145, 182-195 (2010
72. Loverde S. M., Klein M. L. & Discher D. E. Nanoparticle shape improves delivery: rational coarse grain molecular dynamics (rCG MD) of taxol in worm-like PEG-PCL micelles. Adv. Mater. 24, 3823-3830 (2012
73. Perry J. L., Herlihy K. P., Napier M. E. & Desimone J. M. PRINT: a novel platform toward shape and size specific nanoparticle theranostics. Acc. Chem. Res. 44, 990-998 (2011
74. Verma A. & Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 6, 12-21 (2010
75. Kolhar P., et al. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc. Natl Acad. Sci. USA 110, 10753-10758 (2013
76. Perry J. L., et Al. PEGylated PRINT Nanoparticles: The Impact of PEG Density on Protein Binding Macrophage Association Biodistribution and Pharmacokinetics. Nano Lett. 12, 5304-5310 (2012
77. Deng Y., et al. The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles. Biomaterials 35, 6595-6602 (2014
78. Huhn D., et al. Polymer-coated nanoparticles interacting with proteins and cells: focusing on the sign of the net charge. ACS Nano 7, 3253-3263 (2013
79. Tenzer S., et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nature Nanotechnol. 8, 772-781 (2013
80. Monopoli M. P., Aberg C., Salvati A. & Dawson K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nature Nanotechnol. 7, 779-786 (2012
81. Crooke S. T., et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277, 923-937 (1996
82. Wolfrum C., et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotech. 25, 1149-1157 (2007
83. Rodriguez P. L., et al. Minimal self peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971-975 (2013
84. Panariti A., Miserocchi G. & Rivolta I. The effect of nanoparticle uptake on cellular behavior: disrupting or enabling functions?. Nanotechnol. Sci. Appl. 5, 87-100 (2012
85. Wang Y. & Huang L. A window onto siRNA delivery. Nature Biotech. 31, 611-612 (2013
86. Bumcrot D., Manoharan M., Koteliansky V. & Sah D. W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature Chem. Biol. 2, 711-719 (2006
87. Dominska M. & Dykxhoorn D. M. Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci. 123, 1183-1189 (2010
88. Zhou J., Patel T. R., Fu M., Bertram J. P. & Saltzman W. M. Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials 33, 583-591 (2012
89. Lee J. S., et Al. Gold Poly(β-amino Ester) Nanoparticles for Small Interfering RNA Delivery. Nano Lett. 9, 2402-2406 (2009
90. Dahlman J. E., et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nature Nanotechnol. 9, 648-655 (2014
91. Cheng C. J. & Saltzman W. M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials 32, 6194-6203 (2011
92. Biswas S. & Torchilin V. P. Nanopreparations for organelle-specific delivery in cancer. Adv. Drug Deliv. Rev. 66, 26-41 (2014
93. Madani F., et al. Mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys. 2011, 414729 (2011
94. Schaffer D. V. & Lauffenburger D. A. Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery. J. Biol. Chem. 273, 28004-28009 (1998
95. Boucher Y., Baxter L. T. & Jain R. K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50, 4478-4484 (1990
96. Torosean S., et al. Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. Nanomedicine 9, 151-158 (2013
97. Boucher R. C. An overview of the pathogenesis of cystic fibrosis lung disease. Adv. Drug Deliv. Rev. 54, 1359-1371 (2002
98. Suk J. S., et al. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N acetyl cysteine. Nanomedicine (Lond.) 6, 365-375 (2011
99. Yang M., et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew. Chem. Int. Ed. Engl. 50, 2597-2600 (2011
100. Prabhakar U., et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 73, 2412-2417 (2013
101. Kelkar S. S. & Reineke T. M. Theranostics: combining imaging and therapy. Bioconjug. Chem. 22, 1879-1903 (2011
102. Liu Y., et al. Multifunctional pH sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale 6, 3231-3242 (2014
103. Soppimath K. S., Aminabhavi T. M., Kulkarni A. R. & Rudzinski W. E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70, 1-20 (2001
104. Sengupta S., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436, 568-572 (2005
105. Zhang X., et al. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel. Anticancer Drugs 8, 696-701 (1997
106. Rupp R., Rosenthal S. L. & Stanberry L. R. VivaGel™ (SPL7013 Gel): a candidate dendrimer - microbicide for the prevention of HIV and HSV infection. Int. J. Nanomedicine 2, 561-566 (2007
107. Eliasof S., et al. Correlating preclinical animal studies and human clinical trials of a multifunctional polymeric nanoparticle. Proc. Natl Acad. Sci. USA 110, 15127-15132 (2013
108. Pittet L., et al. Development and preclinical evaluation of SEL 068, a novel targeted synthetic vaccine particle (tSVPTM) for smoking cessation and relapse prevention that generates high titers of antibodies against nicotine. J. Immunol. 188, 75.11 (2012
109. Weiss G. J., et al. First in human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest. New Drugs 31, 986-1000 (2013
110. Werner M. E., et al. Preclinical evaluation of Genexol PM a nanoparticle formulation of paclitaxel as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 86, 463-468 (2013
111. Lee K. S., et al. Multicenter phase II trial of Genexol PM a cremophor-free polymeric micelle formulation of paclitaxel in patients with metastatic breast cancer. Breast Cancer Res. Treat. 108, 241-250 (2008
112. Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013, 238428 (2013
113. Foley C. P., Nishimura N., Neeves K. B., Schaffer C. B. & Olbricht W. L. Real-time imaging of perivascular transport of nanoparticles during convection-enhanced delivery in the rat cortex. Ann. Biomed. Eng. 40, 292-303 (2012
114. Papa S., et al. Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury. ACS Nano 7, 9881-9895 (2013
115. Alqawlaq S., et al. Preclinical development and ocular biodistribution of gemini-DNA nanoparticles after intravitreal and topical administration: towards non-invasive glaucoma gene therapy. Nanomedicine 8, 1637-1647 (2014
116. Alvarez-Romn R., Naik A., Kalia Y. N., Guy R. H. & Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm. Res. 21, 1818-1825 (2004
117. Jean M., et al. Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF 2 and PDGF BB or generation of antibodies. Gene Ther. 16, 1097-1110 (2009
118. Kohane D. S., et al. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J. Biomed. Mater. Res. A 77, 351-361 (2006
119. Kamei T., et al. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2 methacryloxyethyl phosphorylcholine co n butyl methacrylate) in peritoneal metastatic nodules. Cancer Sci. 102, 200-205 (2011
120. Huang Y. H., et al. Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice. Cancer Res. 69, 6184-6191 (2009
121. Kourtis I. C., et al. Peripherally administered nanoparticles target monocytic myeloid cells secondary lymphoid organs and tumors in mice. PLoS ONE 8, e61646 (2013
122. Nagahama R., et al. Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. Arterioscler. Thromb. Vasc. Biol. 32, 2427-2434 (2012
123. de Titta A., et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc. Natl Acad. Sci. USA 110, 19902-19907 (2013
124. Rothenfluh D. A., Bermudez H., O'Neil C. P. & Hubbell J. A. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nature Mater. 7, 248-254 (2008
125. Roa W. H., et al. Inhalable nanoparticles a non-invasive approach to treat lung cancer in a mouse model. J. Control. Release 150, 49-55 (2011
126. Luo Y., et al. An inhalable β2-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung. J. Control. Release 162, 28-36 (2012
127. Mott B., Thamake S., Vishwanatha J. & Jones H. P. Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae. J. Nanopart. Res. 15, 1646 (2013
128. Malhotra M., Tomaro-Duchesneau C., Saha S. & Prakash S. Intranasal delivery of chitosan-siRNA nanoparticle formulation to the brain. Methods Mol. Biol. 1141, 233-247 (2014
129. Ulery B. D., et al. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS ONE 6, e17642 (2011
130. Saffran M., et al. A new approach to the oral administration of insulin and other peptide drugs. Science 233, 1081-1084 (1986
131. Yun Y., Cho Y. W. & Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv. Drug Deliv. Rev. 65, 822-832 (2013
132. des Rieux A., et al. Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv. Drug Deliv. Rev. 65, 833-844 (2013
133. Mane V. & Muro S. Biodistribution and endocytosis of ICAM 1 targeting antibodies versus nanocarriers in the gastrointestinal tract in mice. Int. J. Nanomed. 7, 4223-4237 (2012
134. Jin Y., et al. Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33, 1573-1582 (2012